HighGravityDataEdwards Lifesciences — Feb 11, 2025 release
Fiscal 2024 fourth-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001099800-25-000003
Showing in the filing
Adjusted EPS
“$0.58 to $0.64”
Period
Q1 FY2025
Measure
Company-defined measure
Source
Prose
All guidance in this release · 12
Sales growth (constant currency) for FY2025
“8% - 10%”
Adjusted EPS for FY2025
“$2.40 - $2.50”
Structural heart therapies contributions for FY2026
“Increasing contributions from an expanding set of structural heart therapies”
Adjusted gross profit margin for FY2025
“between 78% and 79%”
Operational SG&A spending for FY2025
“approximately flat at these levels”
SG&A ratio for the long term
“lower SG&A ratio over time”
R&D spending for FY2025
“maintain R&D spending at these levels”
R&D as a percentage of sales for the long term
“moderate R&D as a percentage of sales over time”
Adjusted operating margins for FY2025
“27 to 28%”
Operating profit margin for the long term
“annual operating profit margin expansion thereafter”
Total sales for Q1 FY2025
“between $1.35 and $1.43 billion”
Adjusted EPS for Q1 FY2025
“$0.58 to $0.64”
Exhibit 99.1 · the passage around this item
… earlier in the release
Outlook Edwards' full-year total company and product group sales guidance as well as earnings guidance remain unchanged. For the first quarter of 2025, the company projects total sales to be between $1.35 and $1.43 billion and adjusted EPS of $0.58 to $0.64. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube. 3 Conference Call and Webcast Information The company will be hosting a conference call today at 2:00 p.m. PT to discuss its fourth quarter results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com or www.edwards.com. This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements can sometimes be identified by the use of words such as “may,” “will,” “should,” “anticipate,” “believe,” “plan,” “pro
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.